A company called GlucoVista — which is working on a wearable device that promises to continuously monitor glucose levels for Type 1 and Type 2 diabetes patients with infrared light — has raised $2.7 million from six investors, according to a form D filing with the SEC.
GlucoVista’s CGM-305 wearable captures the natural thermal infrared radiation emitted from the glucose in the blood of a human body in specific wave-lengths. This methodology of glucose monitoring is totally passive — and we would add, yet-to-be-proven — thereby providing true non-invasive glucose testing.
The company is currently conducting clinical studies with hospitals in Israel.
Noninvasive glucose monitoring is one of the holy grails of med tech, particularly through spectroscopy. If proven viable, it could make managing diabetes easier because it would become more of a passive exercise. This in turn would help avoid complications, hospitalization and reduce healthcare costs.
Among the companies in pursuit of getting noninvasive approaches approved are Integrity Applications’ GlucoTrack, Socrates Health Solutions and Grove Instruments.
[Via: MedCityNews]